James Lovgren

Ever wonder why some biotech startups seem to have all the right pieces yet still collapse? The science might be solid, the market potential huge, but if the leadership lacks strategic vision, it’s over before it begins. In this industry, the ability to pivot, make tough calls, and keep your team laser-focused is more valuable than any breakthrough in the lab. Good leaders aren’t just managers—they’re strategists who know when to push, when to pull back, and when to change course entirely. So ask yourself, Are you really leading your biotech startup, or are you just along for the ride? #biotech #leadership #pharma #startups #founders

5

🔫 Ready To Pull The Trigger? 🖇 invest.cytonics.com 🪙 Let us help you make an investment decision by highlighting Cytonics’ achievements and key catalysts in the near future. 🥇 A Track Record Of Excellence As our equity crowdfunding campaign nears its close on May 28 at 11:59 PM PST, Cytonics stands on the brink of transformative growth. We've  advanced through crucial drug development phases, solidifying our position as a leader in regenerative medicine with significant scientific and regulatory achievements. These milestones underscore our transition from a promising biotech startup to a frontrunner in osteoarthritis therapy. With Johnson & Johnson as a notable shareholder and our Phase 1 clinical study progressing towards critical Phase 2 collaborations, we offer a compelling opportunity for investors to engage with a company scaling new heights in medical innovation. This is the most pivotal moment in our Company's 18 year history as we are poised to enter first-in-human human clinical trials. 🤝 Delivering On Promises ✅ Since our last equity crowdfund, we have accomplished every single milestone promised to our investors in our mission of creating the first and only true treatment for osteoarthritis. ✅ Completed GMP manufacturing of lead drug candidate, CYT-108. Completed all preclinical (“IND-enabling”) studies for CYT-108. ✅ Designed the first-in-human Phase 1 clinical trial protocol and submitted to ethics boards for regulatory approval. ✅ Received regulatory approval from AU ethics committees to begin Phase 1 clinical study. ✅ Engaged the Contract Research Organization (Southern Star Research) and clinical sites (Emeritus Research, Novatrials) to conduct the Phase 1 study. ✅ Initiated site initiation visits for Phase 1 human clinical study. ✨ Now, we are on the verge of our most significant drug development milestone to date.  ➡️ We anticipate recruiting our first Phase 1 patient in the next few weeks! ➡️ That patient will be dosed in June 2024. ➡️ We expect our Phase 1 clinical study to complete in June 2025.  ➡️ We will then solicit interest from strategic partners for the Phase 2 clinical trial.  ➡️ A positive Phase 2 dataset will be our catalyst for an exit via IPO or acquisition. ➡️ Johnson & Johnson owns 12% of Cytonics, and will be the first company we approach to discuss an acquisition. ➡️ Alternatively, we may use a positive Phase 2 dataset to access the public markets and raise $100M to fund the final, pivotal Phase 3 clinical trial. 🙌 Ready To Join Us? With over 5,000 shareholders who have invested over $15M over 4 equity crowdfunds, we extend a ❤️ heartfelt thanks to all of our investors for your unwavering belief in our vision. #biotech #biotechnology #arthritis #osteoarthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine #orthopedics #orthopaedics #surgery #investor #FDA #medicine #lifesciences #researchanddevelopment #capitalmarkets #lifestyle

6